The Subject Expert Committee (SEC), on Covid-19 of the Central Drugs Standard Control Organisation (CDSCO) on Monday recommended granting permission to manufacture and market anti-Covid pill molnupiravir for restricted emergency use
The product is expected to be available in a week’s time
DCGI approved the drug based on the review of clinical data
The company will market it under the brand name Molflu
The drug will be marketed under the brand name Molnaflu
The company has developed the API in house at its R&D center in Hyderabad
This product will be manufactured at Lupin's Goa facility in India
The authorization provides an additional treatment option against the Covid-19 virus in the form of a pill that can be taken orally
Flattish volume growth and subdued new launches were key factors for last month
Acquisition provides opportunity to develop cladribine in generalized Myasthenia Gravis (gMG) and Neuromyelitis Optica Spectrum Disorder (NMOSD)
Subscribe To Our Newsletter & Stay Updated
